<DOC>
	<DOCNO>NCT02097251</DOCNO>
	<brief_summary>Emergency access grant treat single patient advance Mucopolysaccharidosis Type 7 UX003 Recombinant Human Beta-glucuronidase ( rhGUS ) Enzyme Replacement Therapy via IV administration every week ( QOW ) 144 week .</brief_summary>
	<brief_title>An Open-Label Treatment Protocol With UX003 rhGUS Enzyme Replacement Therapy Advanced Stage MPS 7 Patient</brief_title>
	<detailed_description />
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<criteria>1 specific patient Confirmed diagnosis MPS 7 base leukocyte fibroblast glucuronidase enzyme assay genetic test confirm diagnosis . Written inform consent parent ( ) legal guardian ( )</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Mucopolysaccharidosis Type 7</keyword>
	<keyword>Sly syndrome</keyword>
	<keyword>UX003</keyword>
	<keyword>Enzyme Replacement Therapy</keyword>
	<keyword>rare disease</keyword>
	<keyword>Lysosomal Storage Disease</keyword>
	<keyword>metabolic disorder</keyword>
</DOC>